Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Inhibitors of Kelch-like ECH-associated protein 1 (Keap1) increase the activity of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) by stalling its ubiquitination and degradation. This enhances the expression of genes encoding proteins involved in drug detoxification, redox homeostasis, and mitochondrial function. Nrf2 activation offers a potential therapeutic approach for conditions including Alzheimer's and Parkinson's diseases, vascular inflammation, and chronic obstructive airway disease. Non-electrophilic Keap1-Nrf2 protein-protein interaction (PPI) inhibitors may have improved toxicity profiles and different pharmacological properties to cysteine-reactive electrophilic inhibitors. Here, we describe and characterize a series of phenyl bis-sulfonamide PPI inhibitors that bind to Keap1 at submicromolar concentrations. Structural studies reveal that the compounds bind to Keap1 in a distinct "peptidomimetic" conformation that resembles the Keap1-Nrf2 ETGE peptide complex. This is different to other small molecule Keap1-Nrf2 PPI inhibitors, including bicyclic aryl bis-sulfonamides, offering a starting point for new design approaches to Keap1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Figure 4 Dose-dependent induction of NQO1 [NAD(P)H-dependent quinone oxidoreductase-1] by selected (A) Keap1-Nrf2 PPI inhibitors: 10 (◀), 11 (▼), 31 (▲), 32 (●), 36 (⧫), and 38 (■) and (B) electrophilic Nrf2 activators: DMF (★) and CDDO-Me (▶).](https://figures.cochat.ai/paper-figures/270851c67c154edc99d52e5367aa1f66/phenyl-bis-sulfonamide-keap1-nrf2-proteinprotein-interaction-inhibitors-with-an-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, another Keap1-Nrf2 PPI inhibitor 74, which combined conformational features significantly similar to the Keap1-Nrf2 ETGE complex, revealed the unique inhibition mechanism and provided an innovative strategy for the development of new Keap1-Nrf2 PPI inhibitors.592”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [592]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Open Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,939 · cited 2×
“Analogues having both carboxylates substituted for carboxamides (compound 60 ) or nitriles (compound 61 ) did not show activity at 10 μ M, results that are consistent with the SAR obtained from the 2-benzyloxy derivatives 40 and 41 .”
InfluentialLigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
Laskowski, R. A., & Swindells, M. B. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200227u · Cited by 6,471
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543
The cellular thermal shift assay for evaluating drug target interactions in cells
Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,474
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated Properties
DUNN, K. C., AOTAKI-KEEN, A. E., PUTKEY, F. R., & HJELMELAND, L. M. (1996) · Experimental Eye Research · doi:10.1006/exer.1996.0020 · Cited by 1,330
Research works printed but not linked: 1
- Valko, K. L. Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization; John Wiley & Sons, Inc.: New Jersey, USA, 2014; p 450.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“592 In summary, inhibition or activation of fundamental pathological interactions presents an alternative therapeutic avenue for AD.”
BackgroundAdvances and challenges in therapeutic targeting of NRF2
Dinkova-Kostova, A. T., & Copple, I. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.003 · Cited by 266
Self-citationThe Role of Organosulfur Compounds as Nrf2 Activators and Their Antioxidant Effects
Egbujor, M. C., Petrosino, M., Zuhra, K., & Saso, L. (2022) · Antioxidants · doi:10.3390/antiox11071255 · Cited by 83
Advances in developing noncovalent small molecules targeting Keap1
Barreca, M., Qin, Y., Cadot, M. E. H., Barraja, P., & Bach, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103800 · Cited by 47
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1–Nrf2 PPI Inhibitor
Otake, K., Ubukata, M., Nagahashi, N., Ogawa, N., Hantani, Y., Hantani, R., Adachi, T., Nomura, A., Yamaguchi, K., Maekawa, M., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00067 · Cited by 30
Metadata
- Authors
- Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., Javid, F., Dinkova-Kostova, A. T., Kozielski, F., & Wells, G.
- Affiliations
- Stevenage Bioscience Catalyst (GB)
- UCL School of Pharmacy (GB)
- University of Dundee (GB)
- Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, U.K.
- University of Huddersfield (GB)
- Corresponding author
- Wells, Geoffrey
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-05-12
- Volume
- 65
- Issue
- 10
- Pages
- 7380-7398
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC9150106
- OpenAlex
- W4280585810
- Cited by
- 33
- References
- 48
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 2
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Huddersfield Research Portal (University of Huddersfield) (submittedVersion, cc-by)
- Funders
- School of Pharmacy, University College London
- Royal Society of Chemistry
- University College London
- Biotechnology and Biological Sciences Research Council (BB/L01923X/1)
- Cancer Research UK (C9344/A10268)
- Maplethorpe Trust
- Bloomsbury Consortium
- MRC Proximity to Discovery
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Keap1, Nrf2, protein-protein interaction inhibitors, ubiquitination, drug detoxification, redox homeostasis, Alzheimer's disease, Parkinson's disease, vascular inflammation, chronic obstructive pulmonary disease
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Protein Binding, Sulfonamides, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c00457
- The paper
- Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., Javid, F., Dinkova-Kostova, A. T., Kozielski, F., & Wells, G. (2022). Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c00457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.